Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented, "Earlier this week, we ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE